Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals mixed signals: strong revenue growth and a solid cash position are positive, but uncertainties regarding trial resizing and market adoption challenges are concerning. The Q&A session highlights management's lack of clarity on critical details, which could undermine investor confidence. Despite promising financials, competitive pressures and public health risks persist, suggesting a neutral stock price movement in the near term.
Key Financial Performance
PEMGARDA net revenues (Q4 2025) $53.4 million for the full year 2025, with Q4 revenues up 31% over Q3 2025 and 25% over Q4 2024. The growth is attributed to increased awareness and adoption in the market.
Cash and cash equivalents (end of 2025) $226.7 million, supported by over $200 million raised in the second half of 2025. This positions the company well for future pivotal data and operational needs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revolution clinical program: The program is aimed at providing protection from symptomatic COVID disease. The DECLARATION study, part of this program, has reached its target enrollment and is designed to assess the safety and efficacy of VYD2311, a next-generation monoclonal antibody.
VYD2311: This antibody is designed as an alternative to COVID vaccination, offering a more scalable and convenient intramuscular form. It is more potent and has a longer half-life than PEMGARDA.
RSV antibody: A highly potent, potentially best-in-class RSV antibody has been identified, which is competitive with current standard of care for neonatal and pediatric populations.
Measles program: Updates on the program are expected in the first half of the year, focusing on the potential medical value of a first and best-in-class antibody.
PEMGARDA commercial growth: PEMGARDA demonstrated growth in Q4 2025, with increased adoption across multiple specialties and a high reorder rate of 77%. The company has expanded its commercial footprint to over 15,000 contracted GPO sites.
Broader commercialization of VYD2311: If approved, VYD2311 is expected to redefine COVID prevention and expand the market beyond the current patient population served by PEMGARDA.
Financial performance: PEMGARDA net revenues grew by 31% in Q4 2025 compared to Q3 2025, and by 25% compared to Q4 2024. Full-year 2025 net revenues totaled $53.4 million.
Cash reserves: The company ended 2025 with $226.7 million in cash and cash equivalents, ensuring financial stability through anticipated pivotal data for VYD2311 in mid-2026.
Focus on monoclonal antibodies: The company is building awareness and understanding of monoclonal antibodies among healthcare professionals, professional societies, and public health entities.
Expansion into long COVID and post-vaccination syndrome: Clinical exploration of antibodies for these conditions is underway, addressing substantial unmet needs.
Pediatric and vulnerable populations: Special interest in addressing medical burdens on the elderly, very young, and immunocompromised individuals.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges that forward-looking statements are subject to various risks, assumptions, and uncertainties, which could cause actual results to differ materially. This includes risks related to regulatory approvals and compliance with FDA guidelines for their products.
Clinical Trial Risks: The DECLARATION clinical trial for VYD2311 faces uncertainties related to attack rates in the community, which could impact statistical power and timing of results. Additionally, the trial may require upsizing to ensure robust efficacy assessment, potentially delaying timelines.
Market Adoption Challenges: Despite growing interest in monoclonal antibodies, the company faces challenges in expanding adoption among healthcare providers and patients. The adoption curve is still developing, and there is a need for continued education and awareness-building efforts.
Economic and Financial Risks: The company is dependent on continued PEMGARDA revenue growth and operational discipline to remain well-capitalized through pivotal data milestones. Any shortfall in revenue or unexpected expenses could impact financial stability.
Competitive Pressures: The company operates in a competitive landscape with other monoclonal antibody providers and vaccine manufacturers. Maintaining a competitive edge in terms of efficacy, safety, and convenience is critical for market success.
Supply Chain and Scalability Risks: The scalability and convenience of VYD2311, including its intramuscular form, are highlighted as advantages. However, any disruptions in supply chain or production could impact the ability to meet market demand.
Public Health and Epidemiological Risks: The ongoing evolution of SARS-CoV-2, including immune-evasive Omicron variants, poses risks to the efficacy of current and future monoclonal antibody treatments. The company must stay ahead of virus variation to maintain product relevance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revolution clinical program: The program is aimed at providing Americans with protection from symptomatic COVID disease. The DECLARATION study, part of this program, has reached its target enrollment and is designed to assess the safety and efficacy of VYD2311 in reducing symptomatic COVID-19. The study may be upsized to add statistical power, with results expected in mid-2026.
VYD2311 Antibody: This next-generation monoclonal antibody is designed as an alternative to COVID vaccination. It is more potent and has a longer half-life than previous antibodies, potentially offering scalable and convenient intramuscular protection. The DECLARATION study will evaluate its effectiveness.
Long COVID and post-vaccination syndrome: Clinical exploration of antibodies for these conditions is planned, with trial designs developed in collaboration with the SPEAR study group. The Advisory Committee on Immunization Practices (ACIP) will discuss these topics in March 2026.
RSV Antibody: A highly potent RSV antibody has been identified, which is competitive with current standard-of-care options for neonatal and pediatric populations. This reflects a focus on addressing substantial medical burdens in vulnerable populations.
Measles Program: An update on the measles program is expected in the first half of 2026, with the potential for a first and best-in-class antibody to address the growing burden of disease.
PEMGARDA Commercialization: Efforts to grow PEMGARDA usage continue, with increasing adoption across multiple specialties and a high rate of reordering. This serves as a foundation for broader commercialization of VYD2311, if approved.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on the potential trial resizing decision in the declaration program and the statistical criteria that would trigger it?
A:The resizing decision depends on event rates and statistical criteria related to powering, which involves a 2x2 matrix of expected vaccine efficacy (VE) and the number of events. If resizing is triggered, it would add approximately 30% more participants to the study, potentially increasing power in case the target efficacy is lower than anticipated. The decision is prespecified to avoid bias, and the management is confident in the study's progress so far.
Q:Are secondary endpoints such as viral load, symptom duration, or health care utilization being collected in the study?
A:Yes, secondary endpoints are being collected, including interactions with the healthcare system. However, the study is not powered to detect low-frequency clinical events like hospitalization or death. The focus remains on preventing symptomatic SARS-CoV-2 infections, which is considered a key regulatory and clinical goal.
Q:Can you provide more details on the measles antibody program and its envisioned use cases?
A:The measles antibody program is being developed for outbreak prophylaxis, pediatric bridge therapy before vaccination, and broader prevention strategies. The antibody could be used for treating active disease, responding to outbreaks, or enhancing vaccine efficacy in young children. The program aims to address gaps in current pediatric vaccination schedules and create medical and economic value.
Q:How well has the trial been able to target hotspot areas for COVID-19, and what is the approach to myocarditis monitoring?
A:The trial has some ability to target hotspot areas using data like clinical sequencing and emergency department reports, but the map of COVID-19 hotspots changes rapidly. For myocarditis monitoring, the focus is on identifying clinical myocarditis events, as the study is not powered to detect rare events. Myocarditis is not expected with antibodies but is being monitored in the context of mRNA-based COVID vaccination.
Q:What are the details of the RSV antibody program, and how does it aim to compete in the market?
A:The RSV antibody program builds on lessons from COVID-19 antibody development, addressing evolutionary drift and known liabilities of existing antibodies. The program aims to create a high-quality antibody that adapts to recent viral evolution. The company sees RSV as part of a broader pediatric strategy and is optimistic about competing in the market with innovative clinical trial designs and product profiles.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the statistical criteria for trial resizing, the exact secondary endpoints being collected, and the envisioned use cases for the measles antibody program. Responses were conceptual and lacked quantitative or detailed information.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACIP
America
COVID vaccine
Committee
Disease
Duke
IDMC
Lindsey
Omicron virus
RSV antibody
Revolution program
Street
Wuhan virus
account PEMGARDA
antibody therapy
assessment
attack rate
basis
burden
care
characterization
declaration upsizing
digit
enrollment
estimate
event study
exposure protein
foundation
health
hematology oncology
infection risk
light
million
morbidity
mortality
placebo trial
power
recruitment
specie
IVVD Transcript
Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call summary reveals mixed signals: strong revenue growth and a solid cash position are positive, but uncertainties regarding trial resizing and market adoption challenges are concerning. The Q&A session highlights management's lack of clarity on critical details, which could undermine investor confidence. Despite promising financials, competitive pressures and public health risks persist, suggesting a neutral stock price movement in the near term.
Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents a mix of positive and negative factors. Strong revenue growth and capital raised are positives, but regulatory and clinical trial uncertainties, along with competitive pressures, pose significant risks. The Q&A section reveals management's vague responses on regulatory coordination, adding to uncertainties. While the company's market strategy for VYD2311 is ambitious, the absence of concrete guidance on overcoming regulatory hurdles tempers optimism. Given these mixed signals, the stock price is likely to remain stable, resulting in a neutral rating.
Invivyd, Inc. (NASDAQ:IVVD) Q1 2025 Earnings Call Transcript
Unknown5-16
The earnings call presents a mixed picture. While there are positive elements such as reduced operating expenses, targeted profitability, and potential non-dilutive funding, there are significant challenges. Regulatory hurdles, competitive pressures, economic factors, and operational risks pose threats. The Q&A reveals management's lack of clarity on regulatory interactions and future plans. Despite some positive aspects, the absence of strong financial metrics or guidance and the challenges faced suggest a neutral stock price movement in the short term.
Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss
Unknown5-15
The earnings call summary presents mixed signals: a reduction in operating expenses and potential non-dilutive funding are positive, but the revenue decrease and competitive pressures are concerning. The Q&A section reveals uncertainties about regulatory interactions and operational disruptions, tempering optimism. The lack of a share repurchase or dividend program further limits positive sentiment. Overall, the positives and negatives balance out, leading to a neutral sentiment.
IVVD Slides
IVVD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
